FRAUENHEILKUNDE GYNÄKOLOGIE UND GEBURTSHILFE
   www.frauenheilkunde.medizin-2000.de 


 
        >    Zurück

 | Home | Linkliste | Suche | Nutzung | Impressum| Kontakt |

 

 

 

Quelle: Journal of the American Medical Association (JAMA)

Auch Naturheilmittel versagen bei der Behandlung der Wechseljahresbeschwerden.

 

Immer mehr Frauen suchen zur Linderung der typischen Beschwerden der Wechseljahre nach einer Alternative zu der mittlerweile als gefährlich eingestuften Hormonersatztherapie (HET).

Dabei verwenden sie in erster Linie Produkte, die sog. Isoflavone enthalten - beispielsweise Extrakte aus Rotklee.

Nun belegt eine im Journal of the American Medical Association (JAMA) publizierte wissenschaftliche Studie, dass diese als Nahrungsmittelzusätze vermarkteten Medikamente die lästigen Hitzewallungen nicht besser unterdrücken als ein wirkungsloses Scheinmedikament (Placebo).


Phytoestrogen Supplements for the Treatment of Hot Flashes: The Isoflavone Clover Extract (ICE) Study

A Randomized Controlled Trial

Jeffrey A. Tice, MD; Bruce Ettinger, MD; Kris Ensrud, MD, MPH; Robert Wallace, MD; Terri Blackwell, PhD; Steven R. Cummings, MD, MPH

JAMA. 2003;290:207-214.

Context Clinical trials demonstrating increased risk of cardiovascular disease and breast cancer among women randomized to hormone replacement therapy have increased interest in other therapies for menopausal symptoms. Dietary supplements containing isoflavones are widely used as alternatives to hormonal therapies for hot flashes, but there is a paucity of data supporting their efficacy.

Objective To compare the efficacy and safety of 2 dietary supplements derived from red clover with placebo in symptomatic menopausal women.

Design, Setting, and Participants Randomized, double-blind, placebo-controlled trial of menopausal women, aged 45 to 60 years, who were experiencing at least 35 hot flashes per week. The study was conducted between November 1999 and March 2001 at 3 US medical centers and included women who were recently postmenopausal (mean [SD], 3.3 [4.5] years since menopause) experiencing 8.1 hot flashes per day. Women were exluded if they were vegetarians, consumed soy products more than once per week, or took medications affecting isoflavone absorption.

Intervention After a 2-week placebo run-in, 252 participants were randomly assigned to Promensil (82 mg of total isoflavones per day), Rimostil (57 mg of total isoflavones per day), or an identical placebo, and followed-up for 12 weeks.

Main Outcome Measure The primary outcome measure was the change in frequency of hot flashes measured by participant daily diaries. Secondary outcome measures included changes in quality of life and adverse events.

Results Of 252 participants, 246 (98%) completed the 12-week protocol. The reductions in mean daily hot flash count at 12 weeks were similar for the Promensil (5.1), Rimostil (5.4), and placebo (5.0) groups. In comparison with the placebo group, participants in the Promensil group (41%; 95% confidence interval [CI], 29%-51%; P = .03), but not in the Rimostil group (34%; 95% CI, 22%-46%; P = .74) reduced hot flashes more rapidly. Quality-of-life improvements and adverse events were comparable in the 3 groups.

Conclusion Although the study provides some evidence for a biological effect of Promensil, neither supplement had a clinically important effect on hot flashes or other symptoms of menopause.

Author Affiliations: Division of General Internal Medicine (Dr Tice), Prevention Sciences Group (Drs Blackwell and Cummings), Department of Medicine (Drs Tice, Blackwell, and Cummings), University of California, San Francisco; Division of Epidemiology, School of Public Health, University of Minnesota and Division of General Internal Medicine, and Department of Medicine, Veterans Affairs Medical Center, Minneapolis (Dr Ensrud); Division of Research, Kaiser Permanente Medical Care Program, Oakland, Calif (Dr Ettinger); Preventive Intervention Center, Department of Epidemiology, University of Iowa, Iowa City (Dr Wallace).

RELATED ARTICLES IN JAMA

This Week in JAMA
JAMA. 2003;290:157.

 

 

WERBUNG


 
ÄRZTE FÜR TIERE e. V. verfolgt zwei grundsätzliche Ziele:
den politischen Tierschutz und die Förderung
tiergestützter Therapieformen.
mehr



Mit der neuen Website StARS (Stray Animal Rights Society) engagiert
sich Ärzte für Tiere e.V. für die bisher schutzlosen Straßentiere
und fordert die umgehende Verabschiedung eines
europaweit geltenden Tierschutzgesetzes. mehr


 

 

     Populäre Allergie-Websites   

      im Info-Netzwerk Medizin 2000
 

SIT, spezifische Immuntherapie, Navigation Allergietherapie allgemein
SIT, spezifische Immuntherapie, Navigation Allergietherapie News
SIT, spezifische Immuntherapie, Navigation Gräser -Impf-Tablette
SIT, spezifische Immuntherapie, Navigation Hausstaub(milben)-Allergie
SIT, spezifische Immuntherapie, Navigation Insektengift-Allergie (Bienen- und Wespengift-Allergie )
SIT, spezifische Immuntherapie, Navigation Lebensmittel-/Nahrungsmittel-Allergie
SIT, spezifische Immuntherapie, Navigation Latex-Allergie
SIT, spezifische Immuntherapie, Navigation Pollen-Allergie
SIT, spezifische Immuntherapie, Navigation Pollen-Asthma-Therapie
SIT, spezifische Immuntherapie, Navigation

spezifische subkutane Immuntherapie (SCIT)

SIT, spezifische Immuntherapie, Navigation sublinguale spezifische Immuntherapie (SLIT)
SIT, spezifische Immuntherapie, Navigation Tierhaarallergie ( Hunde- und Katzenhaar-Allergie)
   

 

 

 

zum Seitenanfang

 


Suche mit Google
® auf den Websites des Info-Netzwerk Medizin 2000


 

 

   

 



Wichtige Themen-Websites im Info-Netzwerk Medizin 2000 
(13.12.2009)
 

 | Herzinsuffizienz Therapie | Herzinsuffizienz Diagnose Herzschrittmacher | Herzkrankheiten Heuschnupfen Therapie | Highlights Forschung |

| Sport Medizin | Sublinguale spezifische Immuntherapie SLIT | Thymus Therapie | Tierhaarallergie | Tierschutz | Totalendoprothese TEP |

| Zuckerkrankheit | Info-Netzwerk Medizin 2000 | Nutzungsbedingungen | Stichwortsuche Info-Netzwerk Medizin 2000 | Impressum |

  

Werbung:
24 h Schlüsseldienst München

Copyright ©  LaHave Media Services Limited